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Background: Although lymph node (LN) status and the LN burden determine the outcome of bladder cancer
patients treated with cystectomy, compelling arguments have been made for the incorporation of LN density
into the current staging system. Here, we investigate the relationship between LN density and clinical outcome
in patients with LN-positive disease, following radical cystectomy for bladder cancer.
Methods: PubMed, SCOPUS, the Institute for Scientific Information Web of Science, and the Cochrane Library
were searched to identify relevant published literature.
Results: Fourteen studies were included in the meta-analysis, with a total number of 3311 patients. Of these 14
publications, 6 studies, (533 patients), 10 studies (2966 patients), and 5 studies (1108 patients) investigated the
prognostic association of LN density with disease-free survival (DFS), disease-specific survival (DSS), and overall
survival (OS), respectively. The pooled hazard ratio (HR) for DFS was 1.45 (95 % confidence interval [CI], 1.10–1.91)
without heterogeneity (I2 = 0 %, p = 0.52). Higher LN density was significantly associated with poor DSS (pooled
HR, 1.53; 95 % CI, 1.23–1.89). However, significant heterogeneity was found between studies (I2 = 66 %, p = 0.002).
The pooled HR for OS was statistically significant (pooled HR, 1.45; 95 % CI, 1.11–1.90) without heterogeneity
(I2 = 42 %, p = 0.14). The results of the Begg and Egger tests suggested that publication bias was not
evident in this meta-analysis.
Conclusions: The data from this meta-analysis indicate that LN density is an independent predictor of clinical
outcome in LN-positive patients. LN density may be useful in future staging systems, thus allowing better
prognostic classification of LN-positive bladder cancer.
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Radical cystectomy with lymph node (LN) dissection
remains the standard treatment for patients with
muscle-invasive urothelial carcinoma of the bladder,
and also for non-muscle-invasive disease, refractory to
intravesical therapy. Pelvic LN involvement occurs in
approximately 25 % of patients undergoing radical
cystectomy for urothelial cancer [1]; when LN positivity is
observed, the 10-year mortality rate can reach 80 %,
despite adjuvant chemotherapy [2, 3]. Although LN
involvement portends a relatively poor prognosis, some
patients exhibit long-term survival following surgery, with,* Correspondence: hhkim@snu.ac.kr
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unless otherwise stated.or without systemic chemotherapy [4]. Efforts have
been made to stratify LN-positive patients according to
different prognostic factors to obtain more individualized
risk estimations. Although several prognostic factors
have previously been reported for LN-positive patients,
predictive factors for survival in LN-positive patients have
not been clearly defined.
The concept of LN density, i.e. the number of LNs
containing metastatic deposits divided by the total number
of LNs removed, was first described for bladder cancer in
2003 [5, 6]. Recent studies have suggested that LN
density is superior to the tumor-node-metastasis (TNM)
classification system [5], and to the absolute number of
positive LNs [5, 7] in predicting disease-free survival
(DFS) and disease-specific survival (DSS). Although radical
surgery alone cures 5–34 % of patients with LN-positiveis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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involved LNs, rather than grossly positive, or multiple LN
involvement [8]. Therefore, LN metastasis (LN status), and
the number of involved LNs (LN burden) determine
the outcome of patients with bladder cancer treated
with cystectomy [8]. Compelling arguments have been
made for the incorporation of LN density into the
current American Joint Committee on Cancer (AJCC)
staging system [9]. The present study aimed to elucidate
the relationship between LN density and clinical outcome
in LN-positive patients with bladder cancer following
radical cystectomy.
Methods
This analysis was conducted in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (Additional file 1) [10].
Data sources and search strategy
PubMed, SCOPUS, the Institute for Scientific Information
Web of Science, and the Cochrane Library were searched to
identify potentially relevant published literature. The search
was performed in August 2014. The search terms used
included “bladder cancer,” “radical cystectomy,” and “lymph
node density.” We also carefully examined the references of
articles and reviews to identify potential additional studies.
Study eligibility
Studies were eligible for inclusion in the meta-analysis if
they met the following criteria: (1) patients studied had
LN-positive bladder cancer; (2) LN density was measured;
(3) the association between LN density and clinical
outcome was investigated; and (4) the full text articles
were published in English. Studies were excluded based
on the following criteria: (1) if they were abstracts, review
articles, case reports, letters, or laboratory studies; (2) if
key information for further analysis was absent; (3) when
part, or all, of the same patient series was included in
more than one publication, the largest sample size, or the
most recent publication was included to avoid duplication
of the same survival data; and (4) when studies did not
report an adjusted hazard ratio (HR) in multivariate
analysis, as the accuracy of HRs without using multi-
variate analysis is uncertain. However, if the result was
negative in univariate analysis and as a result, LN density
could not be included in multivariate analysis, the result
of the univariate analysis was included. Two reviewers
(MK and HSK) independently determined study eligibility.
Disagreements were resolved by consensus.
Data extraction and quality assessments
Using a standardized form, data extraction from each of
the included studies was performed independently by
two reviewers (CK and CWJ). When discrepancies arosebetween two reviewers, discussion with another reviewer
(HHK) was undertaken until a consensus was reached.
Quality assessment in this meta-analysis was carried out
using the REporting recommendations for tumor MARKer
prognostic studies (REMARK) guidelines and quality scale
[11, 12], and included the following study parameters:
(1) inclusion and exclusion criteria; (2) prospective or
retrospective data; (3) sufficient description of patient
and tumor characteristics; (4) sufficient description of LN
density measurement; (5) well-defined study endpoint;
(6) description of patient follow-up period; and (7) identi-
fication of patients lost to follow-up or not available for
statistical analysis. Scores ranged from 0 to 8; studies with
a total score of 8 were considered to show the highest
study quality, whereas a score of 0 indicated studies with
the lowest quality.
Statistical analysis
We calculated the pooled HR with its corresponding
95 % confidence interval (CI) to assess the association of
LN density with survival in LN-positive patients. A HR
of >1 indicated a worse prognosis in patients with higher
LN density, if the 95 % CI did not overlap. If explicit sur-
vival data were not provided, they were calculated from the
available numerical data using methods reported by
Parmer et al. [13]. A meta-analysis was performed using the
DerSimonian and Laird random effects model, applying the
inverse of variance as a weighing factor [14]. Heterogeneity
between studies was estimated by using the Cochran
Q-static and I2 tests [15]. A Q-test with a p-value of <0.05
or an I2 value of >50 % was considered to represent
substantial heterogeneity between studies. We also
used subgroup analysis with meta-regression analysis
to explore the sources of heterogeneity. Funnel plots,
the Begg rank correlation test, and the Egger linear
regression test were applied to explore potential publication
bias, and a p-value of <0.05 was considered significant
[16, 17]. All statistical tests were two-sided, and statistical
significance was defined as p < 0.05. RevMan statistical soft-
ware version 5.0 (the Cochrane Collaboration, Copenhagen,
Denmark) was used in this study. Meta-regression and
publication bias were analyzed using R statistical software
version 2.13.0 (R development Core Team, Vienna, Austria;
http://www.r-project.org).
Results
The search strategy retrieved 253 publications, of which
81 were reviewed for eligibility, with 14 studies finally
included [5, 18–30]. The detailed screening process used
is shown in Fig. 1.
Study characteristics
The characteristics of the selected studies are described in
Table 1. The total number of patients from all of the
Fig. 1 Flow chart of the literature search used in this meta-analysis
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cluded studies were published between 2003 and 2014.
Three studies were conducted in Asian countries, and 11
studies were carried out in non-Asian countries. Among
these 14 studies, although data were collected prospect-
ively in 4 studies, none of selected studies was prospective
study. Different cut-off values were used for LN density.
The quality scores ranged from 3 to 6. As shown in
Table 1, 10 of the 14 studies had quality scores of <5, sug-
gesting that most of the studies were not well designed.
Other characteristics of the eligible studies are reported in
Tables 2 and 3.
Outcomes from eligible studies
Of the 14 publications included in the meta-analysis,
6 studies (533 patients), 10 studies (2966 patients), and 5
studies (1108 patients) investigated the prognostic associ-
ation of LN density with DFS, DSS, and overall survival
(OS), respectively (Tables 3, 4, 5, and 6).
The results of the meta-analysis are shown in Figs. 2, 3,
and 4. Overall, the pooled HR for DFS was 1.45 (95 %
CI, 1.10–1.91), suggesting that a higher LN density was anindicator of poor prognosis for bladder cancer. No
significant heterogeneity was observed among the
studies (I2 = 0 %, p = 0.52) (Fig. 2). A meta-analysis of
10 studies found that higher LN density was significantly
associated with poor DSS (pooled HR, 1.53; 95 % CI,
1.23–1.89). However, significant heterogeneity was found
between studies (I2 = 66 %, p = 0.002) (Fig. 3). Subgroup
analysis with meta-regression analysis showed that the
number of patients (pheterogeneity = 0.0015), median
follow-up (pheterogeneity = 0.0017), and quality scale
(pheterogeneity = 0.0233) were possible explanations for
heterogeneity (Table 7). Meta-analysis of the 5 studies
evaluating the association of LN density with OS
found that a higher LN density predicted a worse out-
come, with a pooled HR of 1.45 (95 % CI, 1.11–1.90).
Inter-study heterogeneity was not significant (I2 = 42 %,
p = 0.14) (Fig. 4).
Publication bias
No obvious asymmetry was evident in the Funnel plots of
any contrast (Figs. 2, 3, and 4). All the p-values for the
Begg and Egger tests for DFS, DSS, and OS were >0.05,
Table 1 Main characteristics of the eligible studies

















Herr [5] 2003 USA 1979–1999 No No No Yes 20 NA 3
Fleischmann [18] 2005 Switzerland 1985–2000 Yes Yes Yes No 20 NA 5
Osawa [19] 2009 Japan 1990–2005 No Yes No No 25 NA 4
Wiesner [20] 2009 Germany 2001–2006 Yes No No No 11 NA 3
Furukawa [21] 2010 Japan 1995–2003 No Yes No No 25 NA 4
Guzzo [22] 2010 USA 1988–2003 Yes Yes No Yes 25 NA 5
Stephenson [23] 2010 USA 1999–2007 No No No No 20 Blind 3
May [24] 2011 Germany 1989–2008 No Yes No Yes 20 NA 5
Jensen [25] 2012 Denmark 2004–2009 Yes Yes Yes Yes 10 NA 6
Morgan [26] 2012 USA 1992–2006 No Yes Yes Yes 20 NA 4
Kassouf [27] 2013 Multination 1993–2005 No Yes Yes No None* NA 4
Masson-Lecomte [28] 2013 France 2002–2011 No No No Yes 20 NA 4
Mmeje [29] 2013 USA 2005–2009 No No Yes Yes 20 NA 4
Kwon [30] 2014 Korea 1990–2011 No Yes Yes No 18 NA 4
LND: lymph node density, NA: not available













Herr [5] 162 67 (36–87) NA Distal common iliac
artery
0 NA 90 (24–180)
Fleischmann [18] 101 67 (35–89) 87/14 Crossing of the ureter
with common iliac artery
0 41 21 (1–191)
Osawa [19] 60 68 (34–84) 48/12 Below the bifurcation
of common iliac artery
(almost) Above iliac
bifurcation (a few)
0 25 41 (4–138)
Wiesner [20] 46 NA NA Inferior mesenteric artery 0 27 22 (1–76)
Furukawa [21] 82 70.3 (42–86) 62/20 Distal common iliac
artery
0 17 33.6 (mean) (2–142)
Guzzo [22] 85 NA 67/18 Bifurcation of common
iliac artery
0 55 46 (3–223)
Stephenson [23] 134 68 (IQR: 59–75) NA Distal common iliac
artery
0 90 23 (IQR: 10–36)
May [24] 477 66.3 (33–86) 376/101 NA 0 159 16
Jensen [25] 43 NA NA Inferior mesenteric artery 0 0 53 (24–83)
Morgan [26] 779 NA 530/249 NA 28 296 NA
Kassouf [27] 1,038 67 (IQR: 60–73) 821/217 Not standardized 0 NA 33 (IQR: 14–69)
Masson-Lecomte [28] 75 65 (31–85) 64/11 Common iliac bifurcation NA 46 40.6 (3–127)
Mmeje [29] 50 69 (mean) (50–83) 38/12 Aortic bifurcation 29 19 39.6 (16–75)
Kwon [30] 179 NA NA Not standardized 0 NA 64.3 (1–231.4)
PLND: pelvic lymph node dissection, NA: not available, IQR: interquartile range
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Herr [5] NA 79 (≤T2)/123/0 54/87/21 13 (2–32) 3.3 NA
Fleischmann [18] NA 0/0/0/19 (T1/2)/53/30 32/69/0 22 (10–43) NA NA
Osawa [19] 0/0/9/51 0/0/0/1/6/38/15 21/39 12 (1–80) 2 (1–12) 23.1 (1.3-100)
Wiesner [20] 0/0/8/38 0/0/0/3/11/24/8 NA 33 (15–77) 3 (1–28) 11 (1–73)
Furukawa [21] 0/0/12/70 0/0/0/0/19/37/26 32/50/0 14.4 (mean) (6–37) 3.1 (mean) (1–12) 25.3 (2.8–100)
Guzzo [22] NA 9 (≤T1)/13/63 (T3/4) NA 16.7 (mean) (5–56) NA NA
Stephenson [23] NA 107 (≤T2)/27 (T3/4) 62/72 (N2/3) 14 (IQR: 9–20) 2 (IQR: 1–3) 17 (IQR: 9–38)
May [24] 79 (≤G2)/398 24 (≤T1)/103/350 (T3/4) 187/290/0 12 (1–66) 2 (1–25) 17.6 (2.3–100)
Jensen [25] NA NA 16/9/18 NA NA NA
Morgan [26] 27 (LG)/741 (HG) 14 (≤T1)/48/131/585 NA 9 (IQR: 4–16) 2 (IQR: 1–3) 25 (IQR: 13–50)
Kassouf [27] NA 65 (≤T1)/176/505/292 NA 18 (IQR: 11–32) 2 (IQR: 1–5) 14.3 (IQR: 6.7–33.3)
Masson-Lecomte [28] NA 0/0/0/2/15/39/19 10/10/6 18 (3–49) 3 (1–35) 19 (2–100)
Mmeje [29] NA 0/1/0/2/13/26/7 NA 19 (mean) (5–35) 3 (mean) (1–12) NA
Kwon [30] NA NA 62/116/1 16 (1–118) 3 (1–37) 17.6 (2.6–100)
LV: lymph node, NA: not available, IQR: interquartile range, LG: low grade, HG: high grade
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These results suggest that publication bias was not evident
in this meta-analysis.
Discussion
Up to 25 % of clinically organ-confined tumors show
evidence of LN metastasis at the time of surgery.
Pathologic specimens from contemporary radical cystec-
tomy series reveal that the rate of LN metastasis increases
from 5 % in non-muscle-invasive bladder tumors (≤pT1),
to 18 % in pT2a, 27 % in pT2b, and 45 % in pT3–4 [2].
Although LN-positivity is an adverse prognostic factor per
se, some LN-positive patients experience long-term
survival following radical cystectomy. Therefore, LN dis-
section may be curative in a selected subset of LN-positive
patients [18]. However, prognostic criteria to identify this
population have not been defined.
Several prognostic factors have previously been reported
for LN-positive patients: (1) pathologic stage of the
primary tumor [6, 31]; (2) presence of lymphovascularTable 4 Estimation of the hazard ratio for disease-free survival
Study HR estimation Co-factors
Fleischmann [18] HR, 95 % CI Extracapsular
Guzzo [22] HR, 95 % CI Age, sex, dive
Jensen [25] HR, 95 % CI Age, sex, pT s
extracapsular
of largest LN,
Masson-Lecomte [28] HR, 95 % CI pT stage, lym
adjuvant chem
Mmeje [29] P value, event no. (univariate) -
Kwon [30] HR, 95 % CI pT stage, pN
HR: hazard ratio, CI: confidence interval, LN: lymph nodeinvasion of the primary tumor [18]; (3) pN stage
using the TNM classification; (4) number of LNs
involved [2,618,20,32]; (5) number of LNs removed at
cystectomy [33–35]; (6) LN density [5, 6]; and (7) the
presence of extracapsular extension [18, 28, 36]. However,
factors predictive of survival in LN-positive patients are
debated.
The pT stage of the TNM classification remains
significant in LN-positive bladder cancer [6, 31]. Although
differentiation between pT2 and pT3 disease seems
unnecessary when LN invasion is present, Stein et al. [6]
have previously shown the prognostic significance of
extravesical tumor extension compared to organ-confined
tumor in LN-positive patients. However, the prognostic
significance of the pN stage is unclear [5, 28], although
risk stratification of recurrence and survival following
radical cystectomy has traditionally been based on TNM
staging. The accuracy of the most recent TNM staging
system has also been questioned [37, 38], as the location of
positive LNs does not seem to have prognostic significance.Analysis results
extension, no. of positive LNs Not significant
rsion type, pT stage, adjuvant chemotherapy Not significant
tage, pN stage, metasis above the aortic bifurcation,
extension, volume dependent LN density, diameter
volume of metastatic LNs
Not significant




stage, no. of positive LNs, adjuvant chemotherapy Not significant
Table 5 Estimation of the hazard ratio for disease-specific survival
Study HR estimation Co-factors Analysis results
Herr [5] P value, event no. pT stage, pN stage, no. of LNs removed, no. of positive LNs Significant
Wiesner [20] HR, 95 % CI No. of LNs removed, no. of positive LNs Significant
Furukawa [21] HR, 95 % CI No. of positive LNs, laterality of positive LNs, adjuvant chemotherapy Significant
Guzzo [22] HR, 95 % CI Age, sex, diversion type, pT stage, adjuvant chemotherapy Not significant
May [24] HR, 95 % CI Age, sex, radical cystectomy time frame, pT stage, pN stage, tumor grade,
concomitant carcinoma in situ, adjuvant chemotherapy, no. of LNs removed
Significant
Jensen [25] HR, 95 % CI Age, sex, pT stage, pN stage, metastasis above the aortic bifurcation, extracapsular
extension, volume dependent LN density, diameter of largest LN, volume of
metastatic LNs
Not significant
Morgan [26] HR, 95 % CI Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed,
adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion
Significant
Kassouf [27] HR, 95 % CI Age, sex, tumor grade, pT stage, margin status, lymphovascular invasion, adjuvant
chemotherapy, concomitant carcinoma in situ
Significant
Masson-Lecomte [28] P value, event no. pT stage, extracapsular extension, adjuvant chemoethrapy Not significant
Kwon [30] HR, 95 % CI pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy Not significant
HR: hazard ratio, LN: lymph node, CI: confidence interval
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adverse prognostic factor. Some studies have demonstrated
decreased DFS and OS associated with an increasing
absolute number of positive LNs [2, 6, 18, 20, 32],
but not all studies have confirmed these findings. In
addition, the cut-off number for positive LNs that influ-
ence outcome is controversial. Furthermore, the total
number of positive LNs does not reflect the tumor
burden, and its significance is influenced by the extent of
the LN dissection. Other studies have demonstrated that
the total number of LNs removed, irrespective of LN
positivity, is a significant prognostic factor [6, 33–35].
Extracapsular extension may be an independent prog-
nostic factor for DFS and DSS in LN-positive bladder
cancer and upper urothelial carcinoma [18, 28, 36].
It has been suggested that LN density is more useful
in stratifying patients with LN-positive bladder cancer.
Herr [5] found that a LN density cut-off of 20 % was
superior to the most recent TNM staging system in
predicting DSS and local recurrence, on multivariate ana-
lysis. Stephenson et al. [23] also suggested that the aggre-
gate LN metastasis diameter, LN density, and extranodalTable 6 Estimation of the hazard ratio for overall survival
Study HR estimation Co-factors
Osawa [19] HR, 95 % CI Histology, no. of p
Guzzo [22] HR, 95 % CI Age, sex, diversion
Stephenson [23] HR, 95 % CI pT stage, aggrega
margin status, ext
Morgan [26] HR, 95 % CI Age, Charlson com
removed, adjuvan
surgeon volume, t
Mmeje [29] P value, event no. (univariate) -
HR: hazard ratio, CI: confidence interval, LN: lymph nodeextension should be considered as the novel predictors in
a revised TNM-staging system. However, despite the
attempts of multiple studies to explore the association
between LN density and its potential association with
disease recurrence or death, the results have been incon-
sistent. For example, none of the new LN-dependent
markers, such as localization within the pelvic cavity,
extracapsular extension, and LN density were independ-
ently significant in the prospective study by Jenson et al.
[25]. To our knowledge, the present meta-analysis is the
first to clarify the association between LN density and
survival in LN-positive bladder cancer using meta-analysis
and systematic review. In this meta-analysis, studies
reporting HRs of cumulative survival rates were qualita-
tively summarized using standard meta-analysis tech-
niques. Fourteen studies, with a total of 3311 LN-positive
patients, stratifying DFS, DSS, and/or OS by LN density
were eligible for inclusion in the meta-analysis. Higher LN
density was independently associated with poorer DFS,
DSS, and OS. As our meta-analysis includes 14 eligible
studies, with a total of 3311 patients, it provides stronger
statistical power and a more precise estimation of resultsAnalysis results
ositive LNs, adjuvant chemotherapy Significant
type, pT stage, adjuvant chemotherapy Not significant
te LN metastasis diameter, lymphovascular invasion,
racapsular extension
Not significant
orbidity index, pT stage, tumor grade, no. of LNs




Fig. 2 Forest plots of disease-free survival by lymph node density. (Left) The horizontal lines correspond to the study-specific hazard ratio (HR)
and 95 % confidence interval (CI), respectively. The area of the squares reflects the study-specific weight. The diamond represents the pooled
results of HR and 95 % CI. (Right) The Begg test funnel plots for publication bias. Each point represents a separate study of the indicated
association. The vertical line represents the mean effects size
Ku et al. BMC Cancer  (2015) 15:447 Page 7 of 10than previously published reports. Moreover, our meta-
analysis was mainly based on adjusted estimates, and
statistical significance was observed for all three end-points,
DFS, DSS, and OS.
However, to reach a convincing conclusion regarding
the value of LN density for the prognosis of LN-positive
bladder cancer, some issues should also be addressed.
First, we considered that the definition of what constitutes
a “lymph node” varies among urological pathologists in
different series. This can impact the nodal yields, and
therefore, the burden of lymph node density. Second, the
cut-off points for LN density were arbitrarily determined
retrospectively, and they have not been validated suffi-
ciently in alternative data sets [8]. Therefore, the threshold
for clinically relevant LN density varies between multiple
studies and has yet to be established. Third, there is no
prospectively evaluated standardized template for pelvic
LN dissection. Some data support the use of LN density
rather than the absolute number of positive LNs when
extended pelvic LN dissection is performed [27]. On the
contrary, LN density may be a less sensitive determinant
of outcome following limited dissection [8]. Additionally,
there were no surgical consistency and uniformity of
techniques between previous studies. Therefore, differentFig. 3 Forest plots of disease-specific survival by lymph node density. (Left
and 95 % confidence interval (CI), respectively. The area of the squares refle
results of HR and 95 % CI. (Right) The Begg test funnel plots for publication b
The vertical line represents the mean effects size.LN dissection templates, and different surgical procedures
may contribute significant bias to a meaningful analysis.
Fourth, the number of LNs removed may affect the value
of LN density. Jeong et al. [39] demonstrated that when
more than 15 LNs were removed, LN density was a
predictive factor for survival. In a report by Kassouf et al.,
LN density proved to be a stronger prognostic factor in
patients with a LN count of ≥25 (HR 4.63) than in patients
with a LN count of <25 (HR 1.62) [27]. Therefore, owing
to interindividual variability in pelvic LN anatomy [40],
LN density may not be a prognostic factor in patients with
little lymphatic tissue. Furthermore, although greater
numbers of LNs removed would most likely correlate with
a more extended LN dissection, LN yield is intimately
related to histological processing, and to the extent of
pathologic review. Fifth, it is not known whether LN
density determines survival any better than currently
established pN categories of the TNM system [8].
Future studies are needed before LN density can be widely
accepted as a staging system or used to replace pN
staging. Finally, in the present study, only 2 reports
used neoadjuvant chemotherapy; and therefore, it is
not enough to determine whether LN density can be
a valid marker for survival following neoadjuvant) The horizontal lines correspond to the study-specific hazard ratio (HR)
cts the study-specific weight. The diamond represents the pooled
ias. Each point represents a separate study of the indicated association.
Fig. 4 Forest plots of overall survival by lymph node density. (Left) The horizontal lines correspond to the study-specific hazard ratio (HR) and
95 % confidence interval (CI), respectively. The area of the squares reflects the study-specific weight. The diamond represents the pooled results
of HR and 95 % CI. (Right) The Begg test funnel plots for publication bias. Each point represents a separate study of the indicated association.
The vertical line represents the mean effects size
Ku et al. BMC Cancer  (2015) 15:447 Page 8 of 10chemotherapy, which may favorably alter the nodal
burden [8]. Additionally, given the use of neoadjuvant
chemotherapy had gained increasing acceptance for
treating invasive bladder cancer, the low rate of neoadju-
vant therapy in this meta-analysis may have limitation
on the generalizability. Further evaluation of the impact
of neoadjuvant chemotherapy on LN density would be
necessary.
Several limitations of this study should be considered.
First, the HRs calculated in our meta-analysis may beTable 7 Subgroup analysis for disease-specific survival












<36 months 4 1643
≥36 months 5 544
Analysis results





HR: hazard ratio, CI: confidence interval
Ph
* for heterogeneity between subgroups with meta-regression analysis
*One study was excluded because the duration of follow-up was not available (Moroverestimated, as many of the included studies obtained
data retrospectively. Thus, adequately designed pro-
spective studies are needed to obtain a more precise esti-
mate. Second, the studies retrieved for our analysis were
limited to those published in English, which may result
in a language bias, although the present analysis does
not support publication bias. Third, varying numbers of
patients, median follow-up time, and quality scale might
contribute to the heterogeneity of results for DSS
found in this study. Although the random-effectsPooled HR (95 % CI) Chi2 (p value) I2 Ph
*
0.0517
1.61 (1.09–2.38) 7.42 (0.06) 60 %
1.51 (1.16–1.97) 12.22 (0.03) 59 %
0.3206
1.57 (1.10–2.22) 11.45 (0.003) 83 %
1.54 (1.02–2.31) 14.19 (0.007) 72 %
1.61 (1.08–2.39) 0.46 (0.5) 0 %
0.0015
1.40 (0.82–2.40) 12.35 (0.01) 68 %
1.55 (1.23–1.95) 14.06 (0.007) 72 %
0.0017
1.85 (1.53–2.24) 2.58 (0.46) 0 %
1.20 (0.91–1.59) 7.43 (0.11) 46 %
0.1626
1.14 (0.69–1.87) 7.37 (0.06) 59 %
1.69 (1.31–2.17) 18.98 (0.002) 74 %
0.0233
1.60 (1.26–2.03) 16.99 (0.009) 65 %
1.08 (0.51–2.30) 8.91 (0.01) 78 %
gan [26])
Ku et al. BMC Cancer  (2015) 15:447 Page 9 of 10model considers heterogeneity, and was used to analyze
the studies with heterogeneities, the conclusions drawn
from this meta-analysis should be approached with
caution. However, heterogeneity of results for DSS
was rigorously quantified and analyzed in our meta-
regression and subgroup analysis, which contributes
to a more reliable conclusion.
Conclusions
In summary, the data from this meta-analysis indicate
that LN density is an independent predictor of clinical
outcome in LN-positive patients following radical cystec-
tomy for bladder cancer. Although LN density may be
related to histological processing and the extent of
pathologic review, it is most likely a reflection of the
quality and extent of pelvic LN dissection. LN density
may be useful in future staging systems, thus allowing
better prognostic classification of LN-positive bladder
cancer following radical cystectomy. However, prospective
validation would be required to define cut-off levels for
LN density.
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